Sanofi is an integrated, global healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. Two segments make up Co.'s business: Pharmaceuticals and Vaccines. The Pharmaceuticals segment covers research, development, production and marketing of medicines, consisting of flagship products, plus a broad range of prescription medicines, generic medicines, and consumer health products. The Vaccines segment includes research, development, production and marketing of vaccines in five areas: pediatric vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines.
  • TickerSAN
  • ISINFR0000120578
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

Eric Le Berrigaud

SANOFI: Praluent patent: a battle lost in Germany, not the war | BUY | EUR92(+20%)

SANOFI - BUY | EUR92(+20%) Praluent patent: a battle lost in Germany, not the war A German court ruled in favour of Amgen Litigation far to an end in the US Praluent is not contributing to Sanofi's FV We keep our Buy rating

Sanofi - December 2016 (LTM): Peer Snapshot

Peer Snapshot: Sanofi - December 2016 (LTM) 4 April 2017 (in US millions) FYE Dec-14 FYE Dec-15 LTM Dec-16 FYE Dec-14 FYE Dec-15 LTM Sep-16 FYE Dec-14 FYE Dec-15 LTM Dec-16

Eric Le Berrigaud

SANOFI: Praluent patent: a battle lost in Germany, not the war | BUY | EUR92(+20%)

SANOFI - BUY | EUR92(+20%) Praluent patent: a battle lost in Germany, not the war A German court ruled in favour of Amgen Litigation far to an end in the US Praluent is not contributing to Sanofi's FV We keep our Buy rating

Team Pharma

ODDO : Feedback from lunch with expert: 2019 ASCO General Meeting

>2019 ASCO General Meeting: No real breakthrough and take-off of targeted oncology - Yesterday, as every year, we invited Professor Morere (head of the oncology and haematology units at the Paul Brousse Hospital in Villejuif) to present his feedback on the 2019 ASCO (American Society of Clinical Oncology) General Meeting, which was held in early June in Chicago. Professor Morere reviewed the main advances and innovations in the world of oncology. Even though this year...

Team Pharma

ODDO : Feedback Déjeuner Expert : ASCO 2019

>ASCO 2019 : édition sans breakthrough et essor de la targeted oncology - Hier, nous avions invité, comme chaque année, le Pr Morere (Responsable des unités Oncologie et Hématologie de l’Hôpital Paul Brousse de Villejuif) afin qu’il nous présente son feedback de l’ASCO 2019 qui s’est tenu début juin dernier à Chicago. Le Professeur a passé en revue les principales avancées et innovations dans le monde de l’oncologie. Même si cette édition a vu moins d’annonces breakth...

Martial Descoutures ...
  • Pierre Corby

Sanofi : Expected indication extension

>New indication extension for Dupixent - The FDA yesterday evening approved Dupixent in a new indication: uncontrolled chronic rhinosinusitis in adults. This new indication is the third for the drug after atopic dermatitis obtained in 2017 and moderate-to-severe asthma approved last year. The FDA used as a basis two phase III trials (LIBERTY) showing a substantial improvement in congestion/nasal obstruction. The drug reduces the size of nasal polyps by improving the a...

Jean-Christophe Dourret

Sanofi : Sanofi - 27 Jun 2019

...

1 director bought

A director at Sanofi-Aventis bought 500 shares at 75.220EUR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board ...

François Maury ...
  • Georges Dieng
  • Team Pharma

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 06/28/2019

...

François Maury ...
  • Georges Dieng
  • Team Pharma

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 28/06/2019

...

Alfred Glaser ...
  • Christophe-Raphaël Ganet
  • Delphine Brault
  • Laurence Hofmann
  • Martial Descoutures
  • Pierre Corby

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 06/27/2019

...

Alfred Glaser ...
  • Christophe-Raphaël Ganet
  • Delphine Brault
  • Laurence Hofmann
  • Martial Descoutures
  • Pierre Corby

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 27/06/2019

...

Ahmed Ben Salem ...
  • Alfred Glaser
  • Antoine Boivin-Champeaux
  • Charles Lepetitpas
  • Christophe Chaput
  • Delphine Brault
  • Emira Sagaama
  • Florent Laroche-Joubert
  • François Maury
  • Georges Dieng
  • Jean Sassus
  • Laurence Hofmann
  • Louis Boujard
  • Martial Descoutures
  • Matthias Desmarais
  • Michael Foundoukidis
  • Nicolas David
  • Philippe Ourpatian
  • Pierre Corby
  • Rémi Adam
  • Stephane Houri
  • Steven Gould
  • Sven Edelfelt
  • Virginie Rousseau
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 04/26/2019

...

With a more favourable environment, SANOFI improves to Positive

SANOFI (FR), a company active in the Pharmaceuticals industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 3 out of 4 stars, as well as its unchanged, defensive market behaviour. The title leverages a more favourable environment and raises its general evaluation to Positive. As of the analysis date June 14, 2019, the closing price was EUR 75.98 and its potential was estimated at EUR 82.39.

Nurhayati Wan

Sanofi

Nurhayati Wan

Sanofi

Nurhayati Wan

Sanofi

Nurhayati Wan

Sanofi

MarketLine Department

Zoetis Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Zoetis Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Zoetis Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Key Highlights ...

MarketLine Department

Wilson Bayly Holmes-Ovcon Limited - Strategy, SWOT and Corporate Finance Report

Summary Wilson Bayly Holmes-Ovcon Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Wilson Bayly Holmes-Ovcon Limited (WBHO) is a engineering and construction company. The company provides building and civil engineering services to retail, residential, commercial, healthcare, hotel and entertainment, industrial and energy infrastructure sectors. Moreover, ...

MarketLine Department

Hypera SA - Strategy, SWOT and Corporate Finance Report

Hypera SA - Strategy, SWOT and Corporate Finance Report Summary Hypera SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Hypera SA (Hypera) formerly, Hypermarcas SA, is a manufacturer of pharmaceutical products. It primarily offers non-prescription (OTC) drugs, prescribed medications, branded, generics and sweeteners. The company markets its products under var...

Eric Le Berrigaud ...
  • Gary Waanders
  • Hugo Solvet
  • Jean-Jacques Le Fur

Healthcare: Five picks in healthcare in Q4 with Fresenius, Galapagos, Genmab, Novartis and Sanofi

Healthcare Five picks in healthcare in Q4 with Fresenius, Galapagos, Genmab, Novartis and Sanofi

Dominic Rose ...
  • Naresh Chouhan

New Asthma Drugs Set to Sell $10bn

Five new drugs will drive the Severe Uncontrolled Asthma market from $4bn today to $10bn by 2023. Our bottom-up model shows that biologic drug penetration could almost double by 2023. We see AZN and Sanofi as material winners in the space and show that consensus is likely too low on Tezepelumab, Fasenra & Dupixent. Fasenra is already winning against Nucala (GSK), the P3 Dupixent asthma data has gone underappreciated and consensus models just $200m for Teze in 2023 in AZN numbers.

Expert Corporate Governance Service (ECGS)

Sanofi - AGM 30 April 2019

ITEM 8: In line with the modified AFEP/MEDEF corporate governance code as revised in June 2018, the company proposes to add a CSR criterion to the annual bonus. We regret that the company does not indicate which CSR indicator will be implemented and whether it will be quantifiable or not. However, the 2019 remuneration policy is better than the previous one, therefore we support item 8. ITEM 10: the company’s disclosure improved compared to last year as now it disclosed achievement rates for each of the financial criteria. However, its transparency remains below French and European standards (...

Jehanne Leroy

Sanofi - Assemblée générale des actionnaires du 30 avril 2019

RémunérationsLa société a amélioré sa communication sur les rémunérations attribuées puisqu’elle communique désormais les taux d’atteinte de chacun des critères financiers du bonus ; cependant, sa communication reste bien en deçà de la transparence de ses pairs français et européens (par exemple, son concurrent suisse Novartis communique à la fois les taux d’atteinte de chacun des critères du bonus, mais également les objectifs qui devaient être atteints). Une communication améliorée permettrait de mieux comprendre les montants attribués ; en effet, en l’état le bonus 2018 de 1 855 800 € ne se...

Sanofi – Proxinvest Corporate Governance Rating ® : C

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

Jehanne Leroy

Proxy Report - 02/05/2018

ITEM 9: The company did not improve its disclosure which remains significantly below market practices. This does not allow shareholders to understand amounts granted regarding performance achieved. For example, Revenue grew by 5.6% at constant exchange rates; but the company estimates that it was achieved “below the target” while Business Net Income decreased by 0.4% and the company estimates that it was achieved “above the target”. This lack of disclosure while the CEO, Mr Brandicourt, received €9.75 M in 2017 is unacceptable. ITEM 4: Mr Brandicourt’s mandate is up for renewal. Although we h...

Jehanne Leroy

Proxy Report - 02/05/2018

Cette année encore, la communication de la société concernant les rémunérations n’est pas améliorée et reste en deçà des pratiques françaises et européennes. Ainsi, la société ne communique toujours pas les taux de réalisation de chacun des critères du bonus annuel, empêchant ainsi une parfaite compréhension des montants attribués : en effet, l’un des critères financiers est en hausse, mais la société l’apprécie « en dessous de la cible » tandis que l’autre critère financier est en baisse, mais la société l’apprécie « au-dessus de la cible ». Ce manque de communication alors que M. Brandicourt...

Dave Nicoski ...
  • Ross LaDuke

Global Equity Strategy

Global equities (MSCI ACWI) are testing 52-week lows as prices have been consolidating over the last 1-2 months. Investors' primary sources of angst continue to revolve around concerns of (1) the global shift toward tighter monetary policy and the potential for perceived policy missteps, (2) trade and tariffs, and (3) the potential negative effects both (1) and (2) may have on global growth. Comments from Fed Chair Powell that interest rates are “just below” the neutral rate and the 90-day tariff ceasefire agreement between the U.S. and China have not been able to calm the markets. In Europe, ...

Jérôme VINERIER

Analyse court terme - SANOFI : Les cours progressent toujours.

La tendance de fond est clairement orientée à la hausse. Les cours progressent toujours. Les objectifs suivants sont à 79,55 € et 82,30 €. La tendance serait invalidée sous le support à 70,84 €.

Jérôme VINERIER

Short term view - SANOFI : Prices are still making progress.

The background trend is clearly bullish. Prices are still making progress. The following targets are at €79.55 and €82.30. The trend would be invalidated below the support at €70.84.

Jérôme VINERIER

Short term view - SANOFI : The background trend is clearly bullish.

The background trend is clearly bullish. The correction is gaining traction. It is too early to qualify this action as a bearish reversal. The trend would be invalidated below the support at €70.84.

Jérôme VINERIER

Analyse court terme - SANOFI : La tendance de fond est clairement orientée à la hausse.

La tendance de fond est clairement orientée à la hausse. La correction en cours gagne en vigueur. Il est trop tôt pour parler de retournement baissier. La tendance serait invalidée sous le support à 70,84 €.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch